Patent application

Sub Rosa Ventures and Cleveland Electric Labs Awarded National Laboratory Technology Licensing Opportunity for Variational Autoencoder for Network Anomaly Detection

Retrieved on: 
Wednesday, November 8, 2023

TWINSBURG, Ohio, Nov. 8, 2023 /PRNewswire/ -- Sub Rosa Ventures (SRV), Cleveland Electric Labs (CEL), and Idaho National Laboratories (INL) have reached an agreement providing SRV exclusive licensing rights to INL's Patent Application No.

Key Points: 
  • TWINSBURG, Ohio, Nov. 8, 2023 /PRNewswire/ -- Sub Rosa Ventures (SRV), Cleveland Electric Labs (CEL), and Idaho National Laboratories (INL) have reached an agreement providing SRV exclusive licensing rights to INL's Patent Application No.
  • BA-1297 Opportunity: Idaho National Laboratory (INL), managed and operated by Battelle Energy Alliance, LLC (BEA), offering the opportunity for SRV to enter into a license and/or collaborative research agreement to commercialize this variational autoencoder for network anomaly detection.
  • "As a small-business leader, I see daily the importance of bringing these types of game-changing capabilities to market on behalf of the National Labs.
  • This capability goes a long way in addressing the many concerns people have in placing their information sharing eggs in one basket."

Kelso Technologies Inc. Key Patent Application Filed for Automated Traction Optimization Method for Vehicle Suspension Systems

Retrieved on: 
Tuesday, September 12, 2023

VANCOUVER, British Columbia and BONHAM, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) reports that it has filed its first Patent application for the Company’s Automated Traction Optimization Method for Vehicle Suspension Systems (“Method”).

Key Points: 
  • VANCOUVER, British Columbia and BONHAM, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) reports that it has filed its first Patent application for the Company’s Automated Traction Optimization Method for Vehicle Suspension Systems (“Method”).
  • The Patent Application forms the Company’s initial proprietary claims and intellectual foundation for its automotive wilderness technologies.
  • This patent application filing begins the Company’s comprehensive proprietary protection program for its current and future technologies.
  • Our patent pending technology and its subsequent developments are expected to significantly improve wilderness access, worker safety, operational efficiencies and economic advantages to numerous market segments.”
    James R. Bond CEO of the Company comments: “Kelso is excited to file the first patent application for its automated traction optimization method for vehicle suspension systems.

Cardio Diagnostics Holdings, Inc Announces Expansion of IP Portfolio in Australia with Notice of Allowance of Patent Application

Retrieved on: 
Wednesday, August 2, 2023

2017277666, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.”

Key Points: 
  • 2017277666, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.”
    The patent was exclusively licensed to the Company from the University of Iowa Research Foundation (UIRF).
  • It was co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively.
  • "Securing this Australian patent is a significant step forward in enhancing our intellectual property portfolio globally," stated Dr. Dogan.
  • This Australian patent complements its three other granted patents, in the U.S., Europe, and China, further strengthening Cardio Diagnostics’ robust intellectual property portfolio.

Opteev Develops World's First Multiplex Biochip That Precisely Identifies COVID, Flu, RSV, and Respiratory Pathogens in Under 1 Minute

Retrieved on: 
Monday, July 31, 2023

The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute.

Key Points: 
  • The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute.
  • "With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies.
  • As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip.
  • For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com .

Race executes global license agreement with City of Hope to access FTO IP

Retrieved on: 
Monday, July 10, 2023

--ENDS--

Key Points: 
  • Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States.
  • Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the FTO pathway.
  • Agreement grants Race freedom to explore and operate under certain City of Hope patent rights, subject to specified conditions.
  • Agreement builds engagement with City of Hope and the related opportunity for scientific collaboration as Race progresses its evaluation of bisantrene's targeted impact on the FTO and m6A[1] pathways.

Race executes global license agreement with City of Hope to access FTO IP

Retrieved on: 
Monday, July 10, 2023

These rights granted under the Agreement include the exclusive license of IP potentially arising from a patent application (PCT Application No.

Key Points: 
  • These rights granted under the Agreement include the exclusive license of IP potentially arising from a patent application (PCT Application No.
  • PCT/US2020/043294) ("Patent Application") as filed by City of Hope and know-how relating to data included in the Patent Application ("Know-How").
  • The Agreement ensures Race's exclusive access to that IP, which the Company believes will construct a transparent path for collaborative research and the downstream commercialisation of FTO inhibitory applications.
  • CEO and Managing Director, Damian Clarke-Bruce commented: "In 2020, City of Hope published research highlighting bisantrene as a potent inhibitor of FTO.

ShardSecure® Announces Allowance of Pivotal US Patent Application

Retrieved on: 
Tuesday, June 20, 2023

NEW YORK, June 20, 2023 /PRNewswire/ -- ShardSecure, a leading provider of cloud data security and resilience software, is pleased to announce its receipt of a Notice of Allowance related to our pivotal US patent application covering the current ShardSecure platform.

Key Points: 
  • NEW YORK, June 20, 2023 /PRNewswire/ -- ShardSecure, a leading provider of cloud data security and resilience software, is pleased to announce its receipt of a Notice of Allowance related to our pivotal US patent application covering the current ShardSecure platform.
  • This US Patent is part of the initial ShardSecure patent family, which comprises an Australian Patent, Canadian Patent Application, and EP Patent Application.
  • In addition to this initial patent family, ShardSecure remains focused on protecting its innovation through the filing of at least two new patent families leveraging additional technical improvement of the ShardSecure platform.
  • We anticipate that this US patent will strengthen customer trust in the ShardSecure platform and its specific benefits for data protection."

Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology

Retrieved on: 
Monday, April 3, 2023

WOBURN, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its patent portfolio with one new patent granted in South Korea and two Notices of Allowance in the U.S. and Japan covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore™ platform.

Key Points: 
  • Comera is developing excipients designed to make subcutaneous (SQ) delivery of monoclonal antibodies possible.
  • Comera’s proprietary SQore platform is designed to decrease the viscosity of biologics, such as monoclonal antibodies, when used in high-concentration formulations.
  • The recent developments consist of the following:
    Notice of Allowance from the United States Patent and Trademark Office for expansion of core viscosity reduction patent claims toward antibody formulations and processing improvements with new excipient 1,3-dimethyluracil.
  • “This patent and two Notices of Allowance strengthen Comera’s robust, global patent portfolio with both expansion of claims to our core SQore platform and also geographic expansion outside of the U.S.,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera.

NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra

Retrieved on: 
Tuesday, March 21, 2023

NanoVibronix, Inc ., (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Multiple Frequency Surface Acoustic Waves for Internal Medical Device” (the "Patent Application") related to its UroShield.

Key Points: 
  • NanoVibronix, Inc ., (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Multiple Frequency Surface Acoustic Waves for Internal Medical Device” (the "Patent Application") related to its UroShield.
  • The Patent Application covers a recently developed enhancement to the UroShield product, UroShield “Ultra”, which incorporates improvements to the Company’s original UroShield.
  • The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling and incorporates multiple actuators that work in sequence to discourage bacterial docking by delivering SAWs at multiple frequencies directly to indwelling catheters.
  • UroShield has been proven to be instrumental in improving outcomes for hospital patients suffering from CAUTI.

Cardio Diagnostics Holdings Inc Announces Expansion of IP Portfolio with Notice of Allowance of Patent Application

Retrieved on: 
Thursday, March 2, 2023

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No.

Key Points: 
  • Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No.
  • A Notice of Allowance means that the Chinese Patent Office has determined that the invention meets the requirements for patentability.
  • Patents have already been granted to the same family of intellectual property claims in the United States and Europe.
  • "Cardio Diagnostics is a shining example of the groundbreaking work happening here at the University of Iowa and its global impact.